Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive De-Intensified Radiotherapy Using ctDNA in HPV-Associated Oropharyngeal Cancer
NCT06323460Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Positron emission tomography complete response at 3 months. Started Mar 2024; status: recruiting.
02
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06323460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323460.